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a  b  s  t  r  a  c  t
Advocate® (2.5%  moxidectin  + 10%  imidacloprid)  (Bayer  HealthCare,  Leverkusen,  Germany)
is a multiparasiticidal  spot-on  authorized  for treating  canine  demodicosis  in  many  coun-
tries. This  blinded,  randomized  three-phase  clinical  trial  compared  its  efﬁcacy  employing
different  dosing  regimens  with  that of  ivermectin.  In the  blinded  ﬁrst phase,  58  dogs  suf-
fering  from  generalized  demodicosis  were  randomly  assigned  to one  of  four  groups  and
treated with  monthly,  biweekly  or weekly  applications  of Advocate®, or with  oral  iver-
mectin  (IVR) at  500  g/kg daily.  Dogs  were  evaluated  clinically  and  multiple  skin  scrapings
undertaken  every  4 weeks  until  parasitological  cure  was  achieved  (deﬁned  as  two  consec-
utive series  of deep  skin  scrapings  at monthly  intervals  negative  for  all  life  forms).  Forty
dogs  completed  the  16-week  initial  blinded  phase,  with  5 cases  achieving  parasitological
cure.  Five  dogs  were  deemed  treatment  failures  and  subsequently  treated  with  ivermectin.
The treatment  protocol  was  then  changed  for the remaining  35  dogs  and  this cross-over
phase  (Phase  2)  was  maintained  for  a further  8 weeks  with  an  additional  9  dogs  achieving
parasitological  cure.  Thereafter,  all remaining  animals  were  treated  with  IVR  until  cured
(Phase 3).  Overall,  26  dogs  achieved  parasitological  cure  during  the clinical  investigation.
Of  these,  23  remained  disease-free  for  at least  12  months  while  two  were  lost  to  follow
up  and  one  died  of unrelated  causes.  A total of 32  (55.2%)  dogs  were  withdrawn  at various
stages  of the investigation  including  the 5 dogs  that  were  judged  treatment  failures.  Other
reasons for withdrawal  included:  non-compliance,  lost  to  follow-up,  ivermectin  toxicity  or
reasons  unrelated  to the  investigation.  No  adverse  effects  were  attributable  to the  use of
Advocate®. Parasiticidal  efﬁcacy  was  assessed  by changes  in  mite  counts  (live  adult,  juvenile
and egg)  and skin  lesion  extent  &  severity  scores.  Statistical  signiﬁcance  was  assessed  using
ANCOVA  with initial  mite  counts  or skin  scores  used  as the  covariate  to account  for  varia-
tions  in  disease  severity.  Planned  pairwise  comparisons  were  used  to identify  differences
between  treatment  groups.  The  efﬁcacy  of Advocate® increased  with  its rate of  application
across  all measures  of  efﬁcacy.  Although  ivermectin  was  shown  to  be  more  effective  than
∗ Corresponding author. Tel.: +1 473 4053643; fax: +1 473 4352997.
E-mail address: tpaterson@sgu.edu (T.E. Paterson).
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Advocate® applied  once  weekly,  both  treatment  protocols  produced  clinically  satisfactory
results.  It was  concluded  that  weekly  application  of Advocate® can  be  recommended  as
effective  for  the  treatment  of canine  generalized  demodicosis  without  the  potential  for
toxicity associated  with  ivermectin.
rs.  Pub
BY-NC
2.2. Diagnostic workup© 2014  The  Autho
1. Introduction
It is accepted that Demodex canis is a normal inhabi-
tant of the cutaneous ﬂora of dogs albeit in small numbers
(Ravera et al., 2013) and is acquired from the dam dur-
ing nursing (Greve and Gaafar, 1966). The skin lesions
attributable to demodicosis are a result of an abnormal
proliferation of the mites often compounded by secondary
bacterial infection. Demodicosis can be subdivided into
localized and generalized forms as well as juvenile and
adult onset, with the latter usually associated with an
underlying systemic disease. Generalized demodicosis can
be further subdivided into squamous and pustular forms,
with the latter associated with secondary bacterial infec-
tion. It is often claimed that localized and generalized forms
are distinct and separate entities, however the distinction
between the two is somewhat arbitrary, and most cases
of generalized demodicosis were localized at onset. The
juvenile-onset generalized form is believed to be inherited
with breed predilections shown especially for the Ameri-
can Staffordshire bull terrier, the Staffordshire bull terrier
and the Chinese shar-pei with odds ratios of 35.6, 17.1 and
7.2, respectively, in a study of 2767 cases (Plant et al., 2010).
Although the precise method of inheritance remains spec-
ulative, a signiﬁcant association with the dog leukocyte
antigen Class II alleles has recently been shown (It et al.,
2010). The factors that trigger the proliferation of mites
leading to generalized disease also remain speculative. It
has been claimed that this results from an antigen-speciﬁc
and/or generalized immunosuppression (Barta et al., 1983;
Corbett et al., 1975). However, the nature of this defect
and its relevance to the disease is still a subject of con-
troversy (Lemarie and Horohov, 1996; Felix et al., 2012;
Singh et al., 2010). Failure of the skin innate immunity has
been implicated in the proliferation of Demodex mites in
rosacea in man  (Bevins and Liu, 2007) but its role in canine
demodicosis has yet to be investigated.
Demodicosis is a frustrating disease to treat with
an unpredictable course. While the majority of cases of
localized disease resolve spontaneously, most cases of
generalized demodicosis require aggressive miticidal and
supportive therapy. Amitraz remains one of the few treat-
ments licensed for this purpose world-wide but with
widely varying reports of efﬁcacy (Muller, 1983; Scott and
Walton, 1985; Medleau and Willemse, 1995; Hugnet et al.,
2001). However, due to its potential toxicity and incon-
sistent efﬁcacy, there has been increasing interest in the
use of the macrocyclic lactones. The most widely used is
ivermectin given at 400–600 g/kg orally once per day
until parasitological cure (Mueller, 2004; Mueller et al.,
2012). However, not only is this treatment contraindi-
cated in collies and other herding breeds that have the
ABCB1-1 (MDR1) mutation, but chronic toxicity is notlished  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
uncommonly reported in dogs that are homozygous nor-
mal  (Bissonnette et al., 2009). Other macrocyclic lactones
employed with varying success are milbemycin (Holm,
2003), moxidectin (Wagner and Wendleberger, 2000) and
doramectin (Murayama et al., 2010). Reported efﬁcacy
of these compounds varies, and it remains unclear as to
whether they are signiﬁcantly less toxic than is ivermectin.
Moxidectin has more recently been introduced as a top-
ical spot-on in association with imidacloprid, and marketed
worldwide as Advocate® and as Advantage Multi® in North
America by Bayer HealthCare (Leverkusen, Germany). It is
licensed for the treatment of generalized demodicosis in
a number of countries. Initially, it was labelled for once
monthly application (Heine et al., 2005), but later stud-
ies suggested that it was more efﬁcacious when applied
more frequently (Mueller et al., 2009). Its safety at higher
than labelled doses has been demonstrated in two studies
(Paul et al., 2004; Fourie et al., 2009). In a previous publi-
cation, we  compared the efﬁcacy of weekly, biweekly and
monthly Advocate® with ivermectin administered orally at
500 g/kg for 16 weeks, and showed that weekly treatment
was  signiﬁcantly more efﬁcacious than monthly adminis-
tration, and that the response to ivermectin did not differ
signiﬁcantly from that to weekly Advocate® (Paterson et al.,
2009). We  now report the results of a long-term study
which includes: additional study participants, a cross-over
phase and long-term follow-up.
2. Materials and methods
2.1. Dogs
Dogs included were patients presented to the St.
George’s University Small Animal Clinic, St George’s,
Grenada, or recruited by two welfare organizations on the
island, namely the Grenada Society of Prevention of Cru-
elty to Animals (GSPCA) and Pothounds Against Pregnancy
(PAP).
They were considered for admission to the study if
suffering from generalized demodicosis—as deﬁned by a
minimum of 5 affected areas (>10 cm2 each) or a sin-
gle large affected body region (>100 cm2) or at least one
affected paw, all conﬁrmed by demonstration of mites
upon deep skin scrapings. They were of either sex, >7
weeks of age and weighing >4 kg. Exclusion criteria were
pregnancy, lactation or history of recent parenteral corti-
costeroid usage for ≥4 weeks or use of a parasiticidal agent
with known demodicidal activity within the past 4 weeks.Potential enrolees were subjected to a full clinical
examination by the Principal Investigator (PI) including
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s detailed a history as was possible. Laboratory workup
ncluded a complete blood count and screening for infec-
ion with heartworm, ehrlichiosis, lyme disease and/or
naplasmosis using either Idexx 3Dx® or 4Dx® SNAP® test
Idexx Laboratories, Westbrook, Maine). Clinical evidence
f staphylococcal pyoderma was conﬁrmed by cytology
rom either impression smears or acetate tape preparations
tained with DifQuik (Jorgensen Laboratories, Loveland,
O, USA). Bacterial culture and sensitivity testing was per-
ormed on cases with extensive lesions and/or a failure to
espond to previous antibiotic therapy, by sampling intact
ustules (where present) or purulent exudate (Miller et al.,
013).
.3. Pre-enrolment treatments
Participants were treated for endoparasites as appropri-
te with pyrantel pamoate (Columbia Laboratories, Lexing-
on, Kentucky) or praziquantel/oxantel pamoate/pyrantel
amoate (Paratak Plus®, Bomac, Auckland, New Zealand).
o other parasiticidal products were permitted with the
xception of a pyrethrin spray for ﬂea control where
equired (Adams Flea and Tick SprayTM, Farnham Pet Prod-
cts, Phoenix, Arizona). Dogs testing positive for Diroﬁlaria
mmitis received a minimum of one dose of ivermectin
Heartgard®, Merial, Duluth, Georgia) as a microﬁlari-
ide in addition to adulticide therapy with melarsamine
ydrochloride (Immiticide®, Merial). Those with clinical or
erological evidence of tick-borne disease (Ehrlichia canis
r Anaplasma platys)  were treated with a 3-week course
f doxycycline at 5–10 mg/kg twice daily (multiple man-
facturers). Where antibiotic therapy was required for
yoderma, a minimum of 3 weeks of oral cephalexin (mul-
iple manufacturers; 22–30 mg/kg twice daily) was  given
r an alternative antibiotic if indicated by results of sensi-
ivity testing. Antibiotic therapy was continued or repeated
uring the trial as necessitated by clinical judgement. Sup-
lemental topical antibacterial therapy was also employed
sing SulfOxydex®, Oxydex® or Malaseb® shampoo (DVM
harmaceuticals distributed by Teva Animal Health, St.
oseph, MO). Shampoo therapy was not permitted 48 h
ither side of the day on which topical treatment was
dministered.
.4. Demodicidal products employed
Advocate® (spot-on) (Bayer HealthCare) which contains
0% imidacloprid and 2.5% moxidectin (ADV) applied at the
ecommended dose: dogs 4–10 kg, 1.0 mL;  dogs 10–25 kg,
.5 mL;  dogs 25–40 kg, 4.0 mL.
Ivomec® (Merial) containing 10 mg/mL  of ivermectin
IVR) administered orally at 500 g/kg once daily.
.5. Therapeutic protocol and blinding
.5.1. Phase 1 (blinded)
When admitted to the study, dogs were assigned to one
f four treatment groups by the trial technician, according
o a previously determined, computer-generated random-
zation schedule namely:itology 205 (2014) 687–696 689
(1) ADV1, Advocate® once monthly according to the man-
ufacturer’s instructions.
(2) ADV2, Advocate® every 2 weeks (biweekly).
(3) ADV4, Advocate® weekly.
(4) IVR, ivermectin at 500 g/kg orally once daily.
Medications were dispensed according to the assigned
protocol by the technician in sufﬁcient quantities for one
month, and were administered at the clinic on the ﬁrst
occasion. The owner or responsible person was instructed
regarding the maintenance of the blinding which was
accepted as part of the treatment consent form. The blind-
ing was  maintained for 16 weeks or until parasitological
cure, whichever came ﬁrst. Parasitological cure was  deﬁned
as two consecutive series of skin scrapings undertaken at
monthly intervals that were negative for all life forms, both
dead and alive. It was deemed ethically unacceptable to
maintain an animal on a regimen that might prove inef-
fective, and so any dog that failed to show decreasing mite
counts or whose clinical signs worsened (unless due solely
to pyoderma) when assessed at 8, 12 or 16 weeks, was
judged to be a treatment failure. These dogs were removed
from the study and subsequently treated with IVR. Any case
whose owner was  non-compliant (NC) (deﬁned as failing
to adhere to the therapeutic protocol or failing to present
for re-evaluation as scheduled) was also similarly removed
from the trial.
2.5.2. Phase 2 (cross-over)
Again, in order to avoid maintaining a patient for a long
period on a protocol that could prove to be relatively inef-
fective, the regimen was changed for those who  failed to
achieve parasitological cure within 16 weeks. From this
point on the study was  unblinded and the treatment pro-
tocol changed as follows:
ADV1 (Advocate® once monthly) → ADV2 (Advocate®
biweekly)
ADV2 (Advocate® biweekly) → ADV4 (Advocate®
weekly)
ADV4 (Advocate® weekly) → IVR (ivermectin daily)
IVR (ivermectin daily) → ADV4 (Advocate® weekly)
This regimen was maintained for a further 8 weeks, with
monthly assessments, until parasitological cure. If the ﬁrst
negative skin scraping was achieved during the 8th week of
this phase, the dog was maintained on the same regimen
for a further 4 weeks until the second negative scraping
resulted.
2.5.3. Phase 3 (ﬁnal cure)
Any animal failing to achieve parasitological cure (or
one negative scraping) by the end of the 8 weeks of Phase
2, continued into Phase 3 and was  treated with IVR until
parasitological cure occurred.
2.5.4. Long-term follow up
Following parasitological cure, whenever it occurred,the animals continued to be monitored by the PI for a min-
imum of 12 months via telephone contact and/or clinical
examination. Owners were asked to examine the pet for
development of alopecia, crusting or any dermatological
ry Parasitology 205 (2014) 687–696
Table 1
Summary of canine breeds represented in this clinical trial.
Breed n=
Pothound 38
Pompek 10
Pitbull terrier 4
Rottweiler 2
Belgian malinois 2690 T.E. Paterson et al. / Veterina
problems that resembled their presenting signs. Where any
skin problems were reported, the patient was evaluated at
the clinic and multiple skin scrapings undertaken. All ani-
mals were examined by the PI at the end of the 12-month
follow-up period.
2.6. Data recorded
The majority of the assessments were undertaken by
the PI, but where she was unavailable one of two other
veterinarians who were speciﬁcally trained for the project
performed the examinations. The following series of data
was recorded at each monthly re-evaluation:
2.6.1. Mite counts
At the initial presentation, mite counts were under-
taken from three affected areas. Absolute numbers of each
life stage (adults, juvenile (larvae/nymphs), eggs) were
counted. Live and dead adults were recorded separately
based upon the presence or absence of movement of
mouthparts or legs (Miller et al., 2013) when examined
within 2–3 h of sampling, and the live/dead ratio was  noted.
Mite counts on some animals were extremely high, so
when counts of any life stage exceeded 50, the results were
reported as >50 and assumed to be 50 for purposes of
statistical analysis. The same areas were sampled at each
subsequent evaluation. Where new lesions developed they
were also sampled at the discretion of the PI in order to
further assess clinical progress, but these mite counts were
not included in the dataset.
2.6.2. Skin lesion extent and severity score
This was based upon the principles of the Canine Atopic
Dermatitis Extent and Severity Index (CADESI-03) (Olivry
et al., 2007) but adapted for the lesions of generalized
demodicosis. The extent of dermatological lesions includ-
ing erythema, scales/crusts, comedones/papules/pustules
and alopecia was documented by assigning each lesion type
a score of between 0 (normal) and 6 (extremely severe) for
each of 36 body areas. The maximum total possible score
was thus 864.
2.7. Statistical methods
Statistical analyses were performed with Minitab 16®
(Minitab Inc, State College, Pennsylvania) with P-values
less than 0.5 considered signiﬁcant. For Phase 1 (blinded),
the per cent change in mean counts for each life stage as
well as skin lesion extent and severity score was calculated
and the reduction examined for signiﬁcance by analysis of
covariance (ANCOVA) using the initial score as the covari-
ate to account for variations in the disease severity at the
outset. In the event that signiﬁcant differences were found,
planned pairwise comparisons were conducted. The adult
mite live/dead ratio was also evaluated for prognostic sig-
niﬁcance. For Phase 2 (cross-over), mean scores at the end
of this phase were compared with those at the end of
Phase 1 (blinded) and evaluated using one-sided paired t-
tests. The long-term follow-up data was utilized to evaluate
treatment efﬁcacy based on the number of dogs remain-
ing in remission for a minimum of 12 months. Both theGerman shepherd 1
Great Dane 1
response to treatment and the time to parasitological cure
were calculated based upon the initial group assignment,
but are obviously reﬂective of a combination of treatments
applied due to the cross-over design of this investigation.
2.8. Institutional approval
The clinical investigation protocol was  approved by the
St. George’s University Institutional Animal Care and Use
Committee.
3. Results
3.1. Demographics of the study participants
A total of 58 dogs were enrolled between December
2005 and October 2008 (Table 1). The majority of dogs
(n = 38) included were the local mixed breed known as
“Pothound”. The “Pompek” was  the next most represented
breed, however this more accurately reﬂects the local
small breed dog as opposed to a true ﬁrst generation
cross between Pomeranian and Pekingese. There were
31 males (9/31 neutered) and 27 females (12/27spayed).
Intact females were by chance evenly distributed across
the groups. Ages were not always precisely known but
ranged from 3 months to 12 years. Three cases were
classiﬁed as adult onset, and the remainder as juvenile
onset. Some cases of juvenile onset were up to 4 years of
age when enrolled due to either previous treatment fail-
ures or chronic untreated disease. Sixteen dogs (28%) had
received prior treatment with ivermectin, amitraz or other
unknown medication.
3.2. Clinicopathological ﬁndings
Thirty-eight cases (66%) had pustular demodicosis, and
the remaining 20 (34%) had the squamous form. Antibiotics
employed were generally cephalosporins or less com-
monly, ﬂuoroquinolones. One case developed a multi-drug
resistant Staphylcocccus pseudintermedius infection which
responded slowly to a 16-week course of chlorampheni-
col. Predisposing causes for two of the three adult-onset
cases were severe ehrlichiosis and chronic corticosteroid
usage. No contributing cause was  identiﬁed in the third
case. Ten juvenile-onset cases with ehrlichiosis and one
with D. immitis infection were treated as described above
before beginning the clinical trial.
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Table  2
Summary of results from the 16-week Phase 1 of the trial (blinded). Efﬁcacy of the assigned treatment protocol is reported as a per cent decrease in mite
count or improvement in skin lesion extent and severity score.
Range Per cent reduction in mite counts/skin scores after initial 16 weeks of treatment
ADV1 (%) ADV2 (%) ADV4 (%) IVR (%)
Mean total mite counts 203–330 45 72 82 99
Mean  total live adults 67–123 28 56 83 100
Mean  total juvenile mites 34–58 39 93 90 100
Mean  total egg counts 37–77 24 88 77 100
0
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(v) Live/dead mite ratio: the ratio of live to dead adult
mites proved to be prognostically non-informative in
this study.
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Fig. 1. (a) Per cent reduction in mean total mite counts at end of the 16-Mean  total skin lesion extent
and severity score
155–193 −2
DV1 = Advocate® applied monthly; ADV2 = Advocate® applied biweekly
.3. Withdrawals and treatment failures
Thirty-two cases were withdrawn at various points
uring the study. Five dogs were deemed treatment
ailures—two dogs each from the ADV1 and ADV2 treat-
ent groups, and one from the Advocate® weekly (ADV4)
reatment group. The remaining withdrawals were: 2
ogs that developed ivermectin toxicity, 11 cases of non-
ompliance, 6 deaths from causes unrelated to the study
nd 8 dogs were lost to follow-up.
.4. Phase 1 (blinded)
Forty dogs completed the ﬁrst phase, with 5 cases
chieving parasitological cure–one from the ADV1 group,
nd two each from the ADV2 and IVR groups. Most of the
ogs enrolled were very severely affected, with the major-
ty of total mite counts from the 3 scrapings exceeding
00, with some greater than 500. These numbers repre-
ent underestimates, as each life stage count was capped
nce a count of 50 for that particular life stage was reached.
.4.1. Parasiticidal effects
The mean counts of all life forms decreased during the
6-week period of evaluation across all treatment groups
Table 2). Pre-post ANCOVA analysis revealed signiﬁcant
ifferences between groups (P < 0.001) for all measures of
fﬁcacy. The signiﬁcant differences for each life form were
s follows:
(i) Mean total counts: while there was no signiﬁ-
cant difference in efﬁcacy between monthly (ADV1)
and biweekly (ADV2) application, weekly application
(ADV4) had a signiﬁcantly greater effect than did
biweekly application (P = 0.03) and oral ivermectin
(IVR) was signiﬁcantly more efﬁcacious than was  ADV
weekly application (P = 0.003) (Fig. 1a, Table 2). Since
the total mite count includes dead adults, arguably the
measurement of live adults, juvenile forms and eggs
may  be more reliable indicators.
(ii) Mean total live adult mites: similar to the total mite
counts, IVR treatment led to a signiﬁcantly greater
reduction in live adults than did ADV4 (P = 0.014), and
ADV4 was signiﬁcantly more effective than was ADV2
(P = 0.048) (Table 2). There were no signiﬁcant dif-
ferences observed between monthly and bi-weekly
application.12 57 74
 Advocate® applied weekly; IVR = oral ivermectin.
iii) Mean total juvenile mites: for this measure of efﬁcacy,
ADV2 was more effective than was ADV1 (P < 0.01)
and IVR was  more effective than was  ADV4 (P < 0.001).
Biweekly application (ADV2) proved more effective
than weekly treatment (ADV4) (P < 0.001) (Table 2).
(iv) Mean total egg counts: as was the case for the juvenile
counts, the effect of ADV2 on mean total egg counts
was in fact signiﬁcantly greater than that of ADV4 for
this measure (P = 0.023) and IVR was  more effective
than was  ADV4 (P < 0.001) (Table 2).week Phase 1 (blinded). ADV4 was more effective than ADV2 (P = 0.03)
and IVR was more effective than ADV4 (P = 0.003). (b) Per cent reduction
in  mean skin lesion extent and severity scores at end of the 16-week Phase
1  (blinded). ADV4 was  more effective than ADV2 (P < 0.001) and IVR was
more effective than ADV4 (P < 0.001).
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weeks to parasitological cure based upon treatment proto-Fig. 2. Total mite count exponential decay model demonstrating the
apparent dose-response relationship of treatment with Advocate® .
(vi) Exponential decay models: the relative effectiveness
of the three dosages of Advocate® on total mite counts
is depicted in Fig. 2 with IVR included as a refer-
ence. Monotonically decreasing exponential trends
over time were observed across the treatment groups,
which illustrate the apparent dose-response relation-
ship.
3.4.2. Clinical response
Mean skin lesion extent and severity scores improved
in all treatment groups except ADV1 which demon-
strated a 20% worsening of clinical disease during the
16-week period of evaluation (Fig. 1b, Table 2). Pre-post
ANCOVA again revealed signiﬁcant differences between
groups (P < 0.001). Weekly application (ADV4) was signif-
icantly more effective than biweekly application (ADV2)
(P < 0.001), but there was no difference between the latter
and ADV1 (P = 0.595). IVR was signiﬁcantly more effective
than was ADV4 (P < 0.001).
3.5. Phase 2 (cross-over)
Thirty-ﬁve dogs proceeded from Phase 1 (blinded) to
Phase 2 (cross-over), which was no longer blinded and 28
dogs completed this phase. Nine dogs achieved parasitolog-
ical cure during this phase: ﬁve in the group changing from
IVR to AVD4, two in the group changing from AVD4 to IVR,
two in the group changing from AVD2 to AVD4 and none
of those changing from ADV1 to ADV2. It should be noted
that in four instances, the dogs received their ﬁrst negative
scraping at the end of the two months and were maintained
on the same protocol until their second negative scraping
and hence parasitological cure resulted.
Table 3
Statistical signiﬁcance of improvements in mite counts and skin scores during th
(Gray  denotes signiﬁcance at P < 0.05).
Adult mites Juvenile mites 
ADV1 → ADV2 0.789 0.287 
ADV2  → ADV4 0.051 0.037 
ADV4  → IVR 0.010 0.045 
IVR  → ADV4 0.500 – 
ADV1 = Advocate® applied monthly; ADV2 = Advocate® applied biweekly; ADV4 =itology 205 (2014) 687–696
The statistical signiﬁcance of the measured changes
in mite counts and skin scores that occurred during the
cross-over phase are reported in Table 3. No signiﬁcant
improvements resulted from changing from ADV1 to ADV2.
Those cases that changed from ADV2 to ADV4 showed sig-
niﬁcant reductions in total mites and in juvenile mites
(P = 0.02 and 0.037, respectively). Those dogs proceeding
from ADV4 to IVR showed signiﬁcant improvements in all
parameters, and in the case of dogs changing from IVR
to ADV4, signiﬁcant improvements were noted in total
mite counts and lesions scores (P = 0.039 and 0.040, respec-
tively).
3.6. Phase 3 (ﬁnal cure)
Nineteen dogs that failed to achieve parasitological cure
during the ﬁrst two  phases proceeded to Phase 3 (ﬁnal cure)
and were treated with oral ivermectin. Seven of these were
withdrawn with the remaining 12 dogs achieving parasito-
logical cure.
3.7. Long-term follow up
The 26 dogs that achieved parasitological cure during
the various phases of the study were monitored for a min-
imum of a further 12 months. Two  were lost to follow
up, one died of unrelated causes, but the remaining 23
were still disease-free 12 months later. Two  cases relapsed
after the end of the follow up period—one 15 months
after achieving parasitological cure, and the other after 31
months.
3.8. Time to parasitological cure
Each participant’s time to parasitological cure and the
study phase in which this occurred, are summarized in
Table 4. Five cases cured within Phase 1 (blinded), 9 dur-
ing (or shortly after) Phase 2 (cross-over) and 12 during
Phase 3 (ﬁnal cure). The longest time to cure was  54 weeks
and a number of dogs required treatment in excess of 30
weeks. The mean times to parasitological cure per treat-
ment group ranged from 23.4 to 38.6 weeks. Based upon the
data generated, a generalized linear model was developed
using exponential response and Poisson counts. The resul-
tant model can be used to predict the estimated number ofcol and the patient’s initial mite count (Fig. 3). It should be
emphasized that each treatment group actually represents
a combination of treatments, but of importance is the fact
e 8-week Phase 2 of the trial (cross-over) using one-sided paired t-test.
Mite eggs Total mite count Skin lesion score
0.320 0.542 0.142
0.110 0.020 0.056
0.026 0.007 0.013
– 0.039 0.040
 Advocate® applied weekly; IVR = oral ivermectin.
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Table  4
Details of cases achieving parasitological cure including: patient identiﬁcation number, initial treatment group assignment, time to parasitological cure
(weeks), one-year follow-up results. Time to cure is cited within the phase of the trial in which cure occurred.
Participant
identiﬁcation number
Initial treatment
group assignment
Time to parasitological cure (weeks) and Phase of study in
which it occurred
Remained in remission
for 1 year
Phase 1
(blinded) ADV1
Phase 2
(cross-over) ADV2
Phase 3 (ﬁnal
cure) IVR
04 ADV1 41
√
11  ADV1 45
√
18  ADV1 12
√
19  ADV1 39
√
26  ADV1 28
√
33  ADV1 51
√
34  ADV1 54
√
Phase 1
(blinded) ADV2
Phase 2
(cross-over) ADV4
Phase 3 (ﬁnal
cure) IVR
06 ADV2 30*
√
07  ADV2 16
√
17  ADV2 29* Died 11 months after
remission
35  ADV2 9
√
43  ADV2 33
√
Phase 1
(blinded) ADV4
Phase 2
(cross-over) IVR
Phase 3 (ﬁnal
cure) IVR
05 ADV4 25**
√
14  ADV4 30
√
29  ADV4 32
√
39  ADV4 32
√
40  ADV4 21
√
55  ADV4 36
√
Phase 1
(blinded) IVR
Phase 2
(cross-over) ADV4
Phase 3 (ﬁnal
cure) IVR
01 IVR 37 Lost
02  IVR 17
√
10  IVR 25**
√
12  IVR 20
√
31  IVR 12 Lost
37  IVR 30*
√
42  IVR 29*
√
54  IVR 26**
√
ADV1 = Advocate® applied monthly; ADV2 = Advocate® applied biweekly; ADV4 = Advocate® applied weekly; IVR = oral ivermectin.
* Achieved ﬁrst negative skin scrape at the end of Phase 2. Assigned Phase 2 treatment protocol was continued for an additional 4 weeks as per the study
protocol.
**
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hat irrespective of treatment protocol, the weeks to cure
ncreases proportional to the initial mite count.
.9. Adverse reactions
Side effects that have been reported with the use of
dvocate® include transient pruritus, erythema and vomit-
ng (Fourie et al., 2009), but in this trial no adverse reactions
f any type were seen with any of the three dosage sched-
les. Two dogs developed ivermectin toxicity during the
rial and were subsequently withdrawn from the study due
o the toxicity. Two further dogs that had already been
ithdrawn from the study [one for non-compliance, the
ther due to treatment failure] continued on ivermectin
t the protocol dosage but developed toxicity associated
ith long-term treatment. All cases had moderate to severeek interval on several occasions. Consequently, the ﬁnal evaluation for
neurotoxicosis with bilateral mydriasis, decreased to
absent pupillary light response, ataxia and generalized
muscle weakness. Two dogs had severe-to-complete visual
impairment with concurrent absence of the menace
response, as well as generalized muscle tremors and vom-
iting. The most severe case progressed to coma shortly
after admission to the clinic which lasted for 12 h. All cases
recovered fully within 5–7 days with mydriasis being the
last clinical sign to resolve. One case had been treated with
ivermectin for 6 weeks, two others followed more chronic
administration (∼8 months) and the fourth case is sus-
pected to have resulted from accidental double-dosing on
the same day. At the time of the intoxications, none of the
dogs were receiving any drugs that inhibit P-glycoprotein
which would have increased the animal’s risk for CNS
toxicity. Two  of the dogs were lost to follow up and the
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Fig. 3. Predicted weeks to parasitological cure model based upon
treatment protocol and initial total mite count. Note that results for
ADV4-IVR-IVR and IVR-ADV4-IVR are almost identical and thus appear
superimposed.
remaining two resumed treatment on either ivermectin
tapering up to 500 g/kg orally per day or the ADV4 sched-
ule and continued to parasitological cure.
4. Discussion
Fifty-eight dogs, including a variety of pure breeds,
some cross-breeds and the local mixed breed—Grenadian
pothound, were enrolled into the study. The Pothound is
the most prevalent breed type on the island, and although
no precise epidemiological studies have been undertaken,
it is commonly affected with demodicosis. In Grenada,
there is a large stray population and many animals remain
sexually intact. It is a matter of speculation as to whether
the subjectively high incidence of demodicosis in the dog
population can be accounted for by the gene pool and facil-
itated by random and generally uncontrolled breeding, or
whether it results from the presence of numerous factors
that are often viewed as predisposing, e.g. poor nutritional
status, frequent endo- and ecto-parasitism (Plant et al.,
2010) and endemic infectious diseases, such as ehrlichiosis
and heartworm disease.
Unfortunately, 55% (32/58) of study participants were
withdrawn from the study during the course of the trial.
The most common reason was owner non-compliance
despite the fact that all services and miticidal products
were provided without charge. Among the dogs withdrawn
were ﬁve dogs that were deemed treatment failures—the
treatment failure criterion was introduced to safeguard the
health and welfare of dogs whose poor response to the
assigned treatment could constitute a welfare issue. Never-
theless, these dogs continued to be treated with ivermectin
although their data was not included in the statistical anal-
ysis of the current investigation.All 26 dogs remaining in the study went on to parasito-
logical cure and the 23 that could be followed remained
in remission for at least one year—representing a ∼100%
cure rate. Two dogs were lost to follow-up during this timeitology 205 (2014) 687–696
and another died one month before completing the 12-
month follow-up. Many of the animals in this study were
severely affected since most had never received prior treat-
ment or were poorly managed for months to years resulting
in chronic disease and high mite counts with secondary
bacterial infection. Consequently, individual mite life stage
counts often exceeded 100 for any given sample site, and
so for practical purposes counting ceased at 50. While this
may  have led to an underestimation of mite counts and
ultimately the therapeutic efﬁcacy in the early stages of the
investigation, it would have had no effect on the robustness
of the later analyses. The cure rates in this investigation
are higher than all studies in the literature where similarly
deﬁned cure rates were <90%. However, direct compari-
son of clinical trials for the treatment of canine generalized
demodicosis is difﬁcult as there is a lack of deﬁned stan-
dards of therapeutic efﬁcacy. Some studies report rate of
cure based on the number of animals achieving parasito-
logical cure without long-term follow-up or even based on
single negative skin scrapings, while others have reported
efﬁcacy based on the decrease in mite counts. This investi-
gation followed the currently recommended standard of
efﬁcacy based on the number of animals remaining in
remission for at least one year following parasitological
cure.
Although all dogs achieving parasitological cure
remained in remission for this period, two cases subse-
quently relapsed. One dog relapsed 15 months later, after
his owner was  absent for an extended period of time
and was  suspected to have been malnourished during this
period, while the other dog who  was  suffering from con-
current allergic skin disease relapsed 31 months following
parasitological cure. To the author’s knowledge, glucocorti-
coids were not used to manage the allergic disease. The fact
that these relapses occurred more than one year after par-
asitological cure serves to reinforce the fact that dogs who
have had generalized demodicosis can relapse at any time
and owners should be warned of possible reoccurrence,
especially following episodes of psychological or physio-
logic stress. Recently, Colombo et al. (2012) reported results
from a pilot study which suggested that once monthly
Advocate® may  be effective in the prevention of relapse
of disease in cases of recurrent generalized demodicosis.
Therefore, routine use of this product should be considered
following miticidal treatment as it may  aid in the preven-
tion of subsequent relapse.
Among the ﬁve dogs achieving parasitological cure
during the initial 16-week blinded phase, two received
biweekly application of Advocate®. Coincidentally, these
were the least affected of all study participants, and might
have progressed to self-cure even without intervention.
These two cases appear to be outliers relative to the rest
of the dogs in this treatment group and consequently,
enhanced the apparent efﬁcacy of biweekly application of
Advocate® in this investigation. Although both dogs met
the inclusion criteria, it may  be important to deﬁne mini-
mum  mite counts as a further inclusion criterion in future
clinical trials. This contention is reinforced by the ﬁnding
that the time to cure was shown to increase as a func-
tion of the initial mite count across all treatment groups
(Fig. 3).
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Pharmacokinetic studies have shown that the mox-
dectin in Advocate® reaches a steady-state serum
oncentration (∼36 g/L) after four to ﬁve monthly appli-
ations and that this is signiﬁcantly higher than the
aximum serum concentration following a single dose
15.1 g/L)(Anon, 2009). It is thus likely that weekly appli-
ation of Advocate® enables the serum concentration to
each these elevated steady-state levels more rapidly and
hat these higher concentrations exert more signiﬁcant
iticidal effects. In addition, the fact that the Demodex mite
as a relatively short life cycle of 18–24 days (Soulsby,
982) suggests that treatment should be administered at
east twice monthly for effective disruption of the mite life
ycle.
Although weekly application of Advocate® proved efﬁ-
acious even in the face of severe disease, the response to
aily ivermectin was superior. This is in contrast to our
revious report which was based on smaller numbers and
howed no signiﬁcant difference between the two  treat-
ent protocols (Paterson et al., 2009). However, several
ases of ivermectin toxicity subsequent to chronic use were
ncountered during this trial, whereas no adverse reactions
ollowed the application of Advocate® at any of the dosage
chedules employed. The safety of Advocate® has been
urther established in two published studies. Fourie et al.
2009) reported that 8 dogs with undetermined ABCB1-1
tatus had no signiﬁcant adverse reactions when treated
eekly with 5x the recommended dose for 17 weeks. In an
arlier blinded study, 9 collies that had previously shown
igns of toxicity to the administration of 120 g/kg of iver-
ectin were given 3 applications of Advocate® at 5x the
ecommended dose at monthly intervals and showed no
igns of toxicity (Paul et al., 2004). Although the ABCB1-
 status was not determined, the fact that these animals
ame from a genetic pool of collies with well-documented
ensitivity to ivermectin suggests that they were likely
omozygous mutants.
. Conclusions
This was one of the most detailed long-term studies on
eneralized demodicosis to be undertaken. Of those ani-
als whose owners were fully compliant and could be
ollowed, 100% achieved parasitological cure. Many ani-
als required >30 weeks of treatment, with a maximum of
4 weeks. Irrespective of the treatment protocol, the time
o cure increased as a function of the initial mite count.
he efﬁcacy of Advocate® increased with the frequency
f application at the labelled dose. During the course of
he investigation, the European registration was changed
o permit weekly application in the face of severe dis-
ase, whilst maintaining monthly application in cases of
ild-to-moderate disease. However, it is the opinion of the
uthors that weekly application is the preferred approach
n all cases of canine generalized demodicosis. In this and
ther studies, it was shown to be without side-effects and
ith a wide margin of safety—even in ivermectin-sensitive
ollies. While ivermectin was more effective, toxicity was
ncountered. Perhaps controversially, the latter drug has
een recommended as a treatment for severe generalized
emodicosis under the 2011 clinical practice guidelinesitology 205 (2014) 687–696 695
(Mueller et al., 2012), but it is not licensed for the treatment
of this condition in any country of the world. Further stud-
ies could be warranted to investigate the use of Advocate®
at higher doses and/or a greater frequency of application, to
ascertain whether an equivalent response to that achieved
with ivermectin might result without the associated tox-
icity, thus adhering to the cascade principle operative in
many countries.
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